ABSTRACT
Genetic testing based on next-generation sequencing (NGS) analysis has recently been used to diagnose hereditary diseases. In this study, we explored the usefulness of our custom amplicon panel that targeted 23 genes related to hereditary tumors given in the American College of Medical Genetics and Genomics recommendations. We applied our custom NGS panel to samples from 12 patients previously diagnosed by Sanger sequencing as having the diseases or diagnosed clinically by meeting the diagnostic criteria in this study. Our gene panel not only successfully identified all variants detected by Sanger sequencing but also identified previously unrecognized variants that resulted in confirmation of the disease, or even in the revision of the diagnosis. For instance, a patient identified with an SDHD gene mutation actually had von Hippel-Lindau (VHL) syndrome, as determined by the presence of a pathogenic VHL gene variant. We also identified false-positive results that were generated by amplification of genome regions that are not intended to be investigated. In conclusion, NGS-based amplicon sequencing is a highly effective method to detect germline variants, as long as they are also carefully reviewed by manual inspection.
Subject(s)
High-Throughput Nucleotide Sequencing , Neoplasms , Genetic Testing , Genomics , Humans , Mutation , Neoplasms/geneticsABSTRACT
AIM: To investigate whether Aδ and C fibre pain threshold values, measured using intra-epidermal electrical stimulation (IES), in people with and without Type 2 diabetes are useful in evaluating diabetic polyneuropathy (DPN) severity. METHODS: Aδ and C fibre pain threshold values were measured in Japanese people with (n = 120) and without (n = 76) Type 2 diabetes by IES. Nerve conduction studies and other tests were performed to evaluate diabetic complications. RESULTS: Aδ and C fibre pain threshold values were high in people with diabetes compared with control subjects (Aδ fibre: 0.050 vs. 0.030 mA, P < 0.01; C fibre: 0.180 vs. 0.070 mA, P < 0.01). Participants with diabetes and neuropathy had significantly higher Aδ and C fibre pain threshold values than participants without neuropathy (Aδ fibres 0.063 vs. 0.039 mA, P < 0.01; C fibres 0.202 vs. 0.098 mA, P < 0.05). C fibre pain threshold values were significantly higher in participants with diabetes and diabetic microvascular complications than in participants without complications. Threshold values increased with complication progression. When DPN was diagnosed according to the Diabetic Neuropathy Study Group in Japan criteria, the cut-off for the C fibre pain threshold values was 0.125 mA (area under the curve 0.758, sensitivity 81.5%, specificity 61.5%). The IES test took less time (P < 0.01) and was less invasive (P < 0.01) than the nerve conduction studies. CONCLUSIONS: Intra-epidermal electrical stimulation is a non-invasive and easy measurement of small fibre pain threshold values. It may be clinically useful for C fibre measurement to diagnose early DPN as defined by the Diabetic Neuropathy Study Group in Japan criteria.
Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetic Angiopathies/diagnosis , Diabetic Neuropathies/diagnosis , Erythromelalgia/diagnosis , Nerve Fibers, Unmyelinated/metabolism , Pain Threshold , Polyneuropathies/diagnosis , Diabetic Angiopathies/complications , Diabetic Angiopathies/metabolism , Diabetic Angiopathies/physiopathology , Diabetic Nephropathies/complications , Diabetic Nephropathies/physiopathology , Diabetic Neuropathies/complications , Diabetic Neuropathies/metabolism , Diabetic Neuropathies/physiopathology , Diabetic Retinopathy/complications , Diabetic Retinopathy/physiopathology , Dyslipidemias/complications , Dyslipidemias/epidemiology , Early Diagnosis , Electric Stimulation/instrumentation , Epidermis , Erythromelalgia/complications , Erythromelalgia/metabolism , Erythromelalgia/physiopathology , Female , Humans , Hypertension/complications , Hypertension/epidemiology , Japan/epidemiology , Male , Middle Aged , Point-of-Care Testing , Polyneuropathies/complications , Polyneuropathies/metabolism , Polyneuropathies/physiopathology , Prevalence , Sensitivity and Specificity , Severity of Illness IndexABSTRACT
AIMS: To evaluate 0.75 mg of dulaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, compared with once-daily insulin glargine for glycaemic control in Japanese patients with type 2 diabetes (T2D). METHODS: In this phase III, randomized, open-label, parallel-group, 26-week study, 361 patients with inadequately controlled T2D receiving sulphonylureas and/or biguanides, aged ≥20 years, with glycated haemoglobin (HbA1c) levels 7.0-10.0% (53-86 mmol/mol), inclusive, were randomized (1 : 1) to receive dulaglutide or glargine. Participants and investigators were not masked to treatment allocation. The primary measure was change from baseline in HbA1c at 26 weeks, analysed using a mixed-effects model for repeated measures, with a predefined non-inferiority margin of 0.4%. RESULTS: At week 26, least-squares (LS) mean (standard error) reductions in HbA1c were -1.44 (0.05)% [-15.74 (0.55) mmol/mol] in the dulaglutide group and -0.90 (0.05)% [-9.84 (0.55) mmol/mol] in the glargine group. The mean between-group treatment difference in HbA1c was -0.54% (95% CI -0.67, -0.41) [-5.90 mmol/mol (95% CI -7.32, -4.48)]; p < 0.001. Dulaglutide significantly reduced body weight compared with glargine at week 26 (LS mean difference -1.42 kg, 95% CI -1.89, -0.94; p < 0.001). The most frequent adverse events with dulaglutide treatment were nasopharyngitis and gastrointestinal symptoms. The incidence of hypoglycaemia was significantly lower with dulaglutide [47/181 (26%)] compared with glargine [86/180 (48%)], p < 0.001. CONCLUSION: In Japanese patients with T2D uncontrolled on sulphonylureas and/or biguanides, once-weekly dulaglutide was superior to once-daily glargine for reduction in HbA1c at 26 weeks. Although dulaglutide increased gastrointestinal symptoms, it was well tolerated, with an acceptable safety profile.
Subject(s)
Biguanides/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptides/analogs & derivatives , Hypoglycemic Agents/administration & dosage , Immunoglobulin Fc Fragments/administration & dosage , Insulin Glargine/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Sulfonylurea Compounds/administration & dosage , Aged , Blood Glucose/drug effects , Body Weight/drug effects , Diabetes Mellitus, Type 2/blood , Drug Administration Schedule , Drug Therapy, Combination , Female , Gastrointestinal Diseases/chemically induced , Glucagon-Like Peptides/administration & dosage , Glucagon-Like Peptides/adverse effects , Glycated Hemoglobin/drug effects , Humans , Hypoglycemia/chemically induced , Immunoglobulin Fc Fragments/adverse effects , Japan , Male , Middle Aged , Nasopharyngitis/chemically induced , Recombinant Fusion Proteins/adverse effectsABSTRACT
AIMS: To evaluate the safety and efficacy of empagliflozin for 52 weeks as add-on to one other oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: Patients on biguanide (n = 133), thiazolidinedione (n = 273), α-glucosidase inhibitor (n = 139), dipeptidyl-peptidase-4 inhibitor (n = 139) or glinide (n = 140) were randomized 1 : 1 to receive empagliflozin 10 or 25 mg double-blind as add-on therapy for 52 weeks. Patients on sulphonylurea (SU; n = 336) were randomized 2 : 2 : 1 to receive empagliflozin 10 or 25 mg double-blind or open-label metformin as add-on therapy for 52 weeks. The primary objective was to evaluate safety. Change from baseline in glycated haemoglobin (HbA1c) at week 52 was a secondary endpoint. RESULTS: Adverse events (AEs) were reported in 67.6-84.6% of patients receiving empagliflozin. Confirmed hypoglycaemic AEs (plasma glucose ≤70 mg/dl and/or requiring assistance) were reported in 4.4 and 6.6%, respectively, of patients receiving empagliflozin 10 and 25 mg as add-on to SU and in 0.0 to 2.9%, respectively, of patients receiving empagliflozin 10 and 25 mg as add-on to other therapies. Baseline mean ± standard deviation HbA1c ranged from 7.51 ± 0.73 to 8.06 ± 0.76% across background therapy groups. At week 52, adjusted mean ± standard error changes from baseline in HbA1c ranged from -0.77 ± 0.06 to -1.00 ± 0.06% in patients receiving empagliflozin. CONCLUSIONS: In Japanese patients with T2DM, empagliflozin 10 and 25 mg as add-on to one other oral antidiabetes therapy for 52 weeks were well tolerated and were associated with clinically meaningful reductions in HbA1c.
Subject(s)
Benzhydryl Compounds/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Glucosides/administration & dosage , Hypoglycemic Agents/administration & dosage , Adult , Aged , Benzhydryl Compounds/adverse effects , Biguanides/administration & dosage , Blood Glucose/analysis , Diabetes Mellitus, Type 2/blood , Dipeptidyl-Peptidase IV Inhibitors/administration & dosage , Double-Blind Method , Drug Therapy, Combination , Female , Glucosides/adverse effects , Glycated Hemoglobin/analysis , Glycoside Hydrolase Inhibitors/administration & dosage , Humans , Hypoglycemia/chemically induced , Hypoglycemia/epidemiology , Hypoglycemic Agents/adverse effects , Japan , Male , Metformin/administration & dosage , Middle Aged , Sulfonylurea Compounds/administration & dosage , Thiazolidinediones/administration & dosage , Treatment OutcomeABSTRACT
AIMS: In a phase III study conducted among Japanese patients with type 2 diabetes mellitus (T2DM), linagliptin 5 and 10 mg showed clinically meaningful improvements in glycaemic parameters after 12 and 26 weeks compared with placebo and voglibose, respectively. This extension study assessed long-term tolerability of linagliptin over 52 weeks. METHODS: Japanese patients with T2DM who completed either phase of a 12-week/26-week study comparing linagliptin monotherapy with placebo or voglibose were eligible to enrol. In the extension study, the comparator groups switched to linagliptin 5 or 10 mg, while the linagliptin groups maintained dosage. RESULTS: In all, 540 patients received at least one dose of linagliptin 5 or 10 mg and 494 completed the extension. Long-term treatment with linagliptin was well tolerated; adverse events (AEs) of special interest and serious AEs occurred in small percentages of patients. Drug-related AEs occurred in 10.2 and 10.6% of patients in the linagliptin 5- and 10-mg groups, respectively, and discontinuations due to drug-related AEs occurred in 1.1 and 0.7%, respectively. Only one (0.4%) patient in each dose group experienced investigator-defined hypoglycaemia during the treatment period (both events were non-severe). Body weight was not clinically altered in either group. The glycated haemoglobin A1c profiles over time were similar with linagliptin 5 and 10 mg. CONCLUSIONS: These findings provide evidence for the safety and tolerability of oral linagliptin at either 5 or 10 mg for up to 52 weeks for the treatment of Japanese patients with T2DM, without clinically relevant increase in the risk of hypoglycaemia or weight gain.
Subject(s)
Asian People , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Inositol/analogs & derivatives , Purines/therapeutic use , Quinazolines/therapeutic use , Adult , Aged , Aged, 80 and over , Blood Glucose/drug effects , Blood Glucose/metabolism , Body Mass Index , Body Weight , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/ethnology , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Glycated Hemoglobin/drug effects , Glycated Hemoglobin/metabolism , Humans , Inositol/therapeutic use , Linagliptin , Male , Middle Aged , Time FactorsABSTRACT
AIMS: To evaluate the efficacy and safety of linagliptin 5 and 10 mg vs. placebo and voglibose in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: This study enrolled patients with inadequately controlled T2DM who were previously treated with one or two oral antidiabetics or were drug naÏve. After a 2 to 4-week washout and placebo run-in, 561 patients were randomized (2 : 2 : 2 : 1) to double-blind treatment with linagliptin 5 or 10 mg qd, voglibose 0.2 mg tid or placebo. The primary endpoint was the change from baseline in haemoglobin A1c (HbA1c) with linagliptin vs. placebo after 12 weeks and vs. voglibose after 26 weeks. RESULTS: Baseline characteristics were well balanced across treatment groups (overall mean HbA1c was 8.01%). The adjusted mean (95% confidence interval) treatment differences at week 12 were -0.87% (-1.04, -0.70; p < 0.0001) and -0.88% (-1.05, -0.71; p < 0.0001) for linagliptin 5 and 10 mg vs. placebo and at week 26 were -0.32% (-0.49, -0.15; p = 0.0003) and -0.39% (-0.56, -0.21; p < 0.0001) for linagliptin 5 and 10 mg vs. voglibose. At week 12, mean HbA1c was 7.58, 7.48 and 8.34% in patients receiving linagliptin 5 mg, linagliptin 10 mg and placebo, respectively. At week 26, mean HbA1c was 7.63% with linagliptin 5 mg, 7.50% with linagliptin 10 mg and 7.91% with voglibose. Drug-related adverse event rates were comparable across treatment groups over 12 weeks (9.4% linagliptin 5 mg, 8.8% linagliptin 10 mg and 10.0% placebo) and 26 weeks (11.3% linagliptin 5 mg, 10.6% linagliptin 10 mg and 18.5% voglibose). There were no documented cases of hypoglycaemia. CONCLUSIONS: Linagliptin showed superior glucose-lowering efficacy and comparable safety and tolerability to both placebo and voglibose in Japanese patients with T2DM.
Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 2/drug therapy , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Inositol/analogs & derivatives , Purines/therapeutic use , Quinazolines/therapeutic use , Adult , Aged , Aged, 80 and over , Analysis of Variance , Diabetes Mellitus, Type 2/epidemiology , Dipeptidyl-Peptidase IV Inhibitors/administration & dosage , Dipeptidyl-Peptidase IV Inhibitors/adverse effects , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Humans , Hypoglycemic Agents/therapeutic use , Inositol/therapeutic use , Japan , Linagliptin , Male , Middle Aged , Purines/administration & dosage , Purines/adverse effects , Quinazolines/administration & dosage , Quinazolines/adverse effects , Treatment OutcomeABSTRACT
C/EBP homologous protein (CHOP) has been proposed as a key transcription factor for endoplasmic reticulum (ER) stress-mediated ß-cell death induced by inflammatory cytokines in vitro. However, the contribution of CHOP induction to the pathogenesis of type 1 diabetes is not yet clear. To evaluate the relevance of CHOP in the pathogenesis of type 1 diabetes in vivo, we generated CHOP-deficient non-obese diabetic (NOD.Chop (-/-)) mice. CHOP deficiency did not affect the development of insulitis and diabetes and apoptosis in ß-cells. Interestingly, NOD.Chop (-/-) mice exhibited a delayed appearance of insulin autoantibodies compared to wild-type (wt) mice. Adoptive transfer with the diabetogenic, whole or CD8(+)-depleted splenocytes induced ß-cell apoptosis and the rapid onset of diabetes in the irradiated NOD.Chop (-/-) recipients with similar kinetics as in wt mice. Expression of ER stress-associated genes was not significantly up-regulated in the islets from NOD.Chop (-/-) compared to those from wt mice or NOD-scid mice. These findings suggest that CHOP expression is independent of the development of insulitis and diabetes but might affect the early production of insulin autoantibodies in the NOD mouse.
Subject(s)
Autoantibodies/biosynthesis , Gene Deletion , Insulin/immunology , Prediabetic State/immunology , Prediabetic State/pathology , Transcription Factor CHOP/genetics , Adoptive Transfer , Animals , Apoptosis , Autoantibodies/immunology , CD8-Positive T-Lymphocytes/immunology , Endoplasmic Reticulum/genetics , Endoplasmic Reticulum/pathology , Gene Expression Regulation , In Situ Nick-End Labeling , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/pathology , Lymphocyte Depletion , Mice , Mice, Inbred NOD , Peroxidase/metabolism , Spleen/immunology , Stress, Physiological/genetics , Transcription Factor CHOP/metabolismABSTRACT
AIM: The aim of this study was to evaluate the efficacy of two group-based lifestyle interventions in ameliorating the risk factors of metabolic syndrome (MS) and insulin resistance. METHODS: Ninety-eight subjects who had at least one component of MS were randomized into standard intervention (SI) (4-month intervention; n = 50) and extended intervention (EI) (10-month intervention; n = 48) groups, and 39 subjects were followed up for a control group. The effects of intervention were evaluated after 10, 22 and 34 months. RESULTS: At month 10, the standard and EI groups showed improved body mass index (BMI) (SI, -0.28; EI, -0.47; control, -0.09), high-density lipoprotein (HDL) cholesterol, fasting plasma glucose and A1c and a decreased mean number of components of MS (SI, -0.37; EI, -0.51; control, 0.08). At month 34, the effects on BMI (SI, -0.66; EI, -0.60; control, -0.05) and HDL-cholesterol were sustained for both the intervention groups. In controls, the increases in fasting plasma glucose and the mean number of components of MS from the baseline to month 34 were greater than those in the standard and EI groups. Whole body insulin sensitivity index and hepatic insulin resistance index were also improved at month 10. CONCLUSIONS: Group-based lifestyle intervention could be an efficient way to prevent MS. Its effects were sustainable, at least in part, for 2 years. These effects may be mediated by an improvement in insulin sensitivity.
Subject(s)
Insulin Resistance/physiology , Lipid Metabolism/physiology , Metabolic Syndrome/prevention & control , Risk Reduction Behavior , Adult , Aged , Female , Humans , Japan/epidemiology , Male , Metabolic Syndrome/epidemiology , Metabolic Syndrome/etiology , Middle Aged , Risk FactorsABSTRACT
We report a 36-year-old woman with complex regional pain syndrome (CRPS) type 1 presenting with extensive skin necrosis of the left arm. The patient cooled her arm with ice packs to ease severe pain due to CRPS, in spite of repeated cautions against frostbite injury. The regions of skin necrosis corresponded with the sites where she had applied ice packs. We considered that the severe skin necrosis in our case was due to a self-induced frostbite injury.
Subject(s)
Complex Regional Pain Syndromes/pathology , Frostbite/complications , Skin/pathology , Adult , Arm , Complex Regional Pain Syndromes/therapy , Female , Frostbite/pathology , Humans , NecrosisABSTRACT
A case of a successful surgical treatment for traumatic mitral valve regurgitation is reported. A 44-year-old, small-statured female with cretinism had a traffic accident. Eleven days after the accident, she was admitted to our hospital with severe respiratory distress syndrome by acute pulmonary edema. Echocardiography showed severe mitral regurgitation due to tendon rupture of posterior leaflet. Mitral valve plasty was performed successfully.
Subject(s)
Mitral Valve Insufficiency/etiology , Mitral Valve Insufficiency/surgery , Mitral Valve/surgery , Pulmonary Edema/etiology , Thoracic Injuries/complications , Wounds, Nonpenetrating/complications , Accidents, Traffic , Acute Disease , Adult , Congenital Hypothyroidism , Echocardiography , Female , Heart Failure/etiology , Humans , Mitral Valve Insufficiency/diagnostic imaging , Treatment OutcomeABSTRACT
A 60-year-old female was admitted to our hospital who suffered from palpitation and dyspnea. Echocardiography revealed severe aortic regurgitation and enlargement of ascending aorta. Electrocardiogram showed tachycardia due to atrial fibrillation. We performed the aortic root replacement with Carboseal composite graft and pulmonary vein isolation using Cardioblate BiPolar (BP) system. Histopathologic diagnosis was giant isolated aortitis. The post operative course was uneventful. And the patient was discharged in normal sinus rhythm.
Subject(s)
Aortic Valve Insufficiency/surgery , Aortitis/surgery , Blood Vessel Prosthesis Implantation/methods , Catheter Ablation/methods , Pulmonary Veins/surgery , Aortic Valve Insufficiency/etiology , Aortitis/complications , Aortitis/diagnosis , Female , Heart Valve Prosthesis Implantation/methods , Humans , Middle Aged , Severity of Illness IndexABSTRACT
AIMS/HYPOTHESIS: This multinational study was conducted to investigate the association between a mitochondrial DNA (mtDNA) T16189C polymorphism and type 2 diabetes in Asians. The mtDNA 16189C variant has been reported to be associated with insulin resistance and type 2 diabetes. However, a recent meta-analysis concluded that it is negatively associated with type 2 diabetes in Europids. Since the phenotype of an mtDNA mutant may be influenced by environmental factors and ethnic differences in the nuclear and mitochondrial genomes, we investigated the association between the 16189C variant and type 2 diabetes in Asians. METHODS: The presence of the mtDNA 16189C variant was determined in 2,469 patients with type 2 diabetes and 1,205 non-diabetic individuals from Korea, Japan, Taiwan, Hong Kong and China. An additional meta-analysis including previously published Asian studies was performed. Since mtDNA nucleotide position 16189 is very close to the mtDNA origin of replication, we performed DNA-linked affinity chromatography and reverse-phase liquid chromatography/tandem mass spectrometry and chromatin immunoprecipitation to identify protein bound to the 16189 region. RESULTS: Analysis of participants from five Asian countries confirmed the association between the 16189C variant and type 2 diabetes [odds ratio (OR) 1.256, 95% CI 1.08-1.46, p=0.003]. Inclusion of data from three previously published Asian studies (type 2 diabetes n=3,283, controls n=2,176) in a meta-analysis showed similar results (OR 1.335, 95% CI 1.18-1.51, p=0.000003). Mitochondrial single-stranded DNA-binding protein (mtSSB) was identified as a candidate protein bound to the 16189 region. Chromatin immunoprecipitation in cybrid cells showed that mtSSB has a lower binding affinity for the 16189C variant than the wild-type sequence. CONCLUSIONS/INTERPRETATION: The mtDNA 16189C variant is associated with an increased risk of type 2 diabetes in Asians.
Subject(s)
DNA, Mitochondrial/genetics , Diabetes Mellitus, Type 2/genetics , Genetic Variation , Polymorphism, Single Nucleotide , Asian People/genetics , China , DNA Primers , Diabetes Mellitus, Type 2/epidemiology , Humans , Japan , Korea , TaiwanSubject(s)
Hyaluronic Acid/metabolism , Scalp Dermatoses/metabolism , Adult , Humans , Magnetic Resonance Imaging , MaleSubject(s)
Granuloma/pathology , Herpes Zoster/pathology , Skin Diseases/pathology , Aged, 80 and over , Anti-Allergic Agents/therapeutic use , Female , Granuloma/drug therapy , Granuloma/virology , Herpes Zoster/drug therapy , Humans , Skin Diseases/drug therapy , Skin Diseases/virology , ortho-Aminobenzoates/therapeutic useSubject(s)
Hamartoma/pathology , Skin Diseases/pathology , Williams Syndrome/pathology , Back , Child, Preschool , Humans , MaleSubject(s)
Complex Regional Pain Syndromes/complications , Skin Diseases/pathology , Adult , Atrophy/pathology , Female , Forearm , HumansABSTRACT
To characterize the low-molecular-weight glutenin subunit (LMW-GS), we developed specific PCR primer sets to distinguish 12 groups of LMW-GS genes of Norin 61 and to decide their loci with nullisomic-tetrasomic lines of Chinese Spring. Three, two, and ten groups were assigned to Glu-A3, Glu-B3, and Glu-D3 loci, respectively. To identify the proteins containing the corresponding amino acid sequences, we determined the N-terminal amino acid sequence of 12 spots of LMW-GSs of Norin 61 separated by two-dimensional gel electrophoresis (2DE). The N-terminal sequences of the LMW-GS spots showed that 10 of 12 groups of LMW-GSs were expressed as protein products, which included LMW-i, LMW-m, and LMW-s types. Four spots were encoded by Glu-A3 (LMW-i). Three spots were encoded by Glu-B3 (LMW-m and LMW-s). Five spots were encoded by Glu-D3 (LMW-m and LMW-s). A minor spot of LMW-m seemed to be encoded by the same Glu-B3 gene as a major spot of LMW-s, but processed at a different site. Comparing among various cultivars, there were polymorphic and non-polymorphic LMW-GSs. Glu-A3 was highly polymorphic, i.e., the a, b, and c alleles showed one spot, the d allele showed four spots, and the e allele had no spot. Insignia used as one of the Glu-A3 null standard cultivars had a LMW-GS encoded by Glu-A3. We also found that Cheyenne had a new Glu-D3 allele. Classification of LMW-GS by a combination of PCR and 2DE will be useful to identify individual LMW-GSs and to study their contribution to flour quality.
Subject(s)
Glutens/chemistry , Glutens/genetics , Triticum/genetics , Triticum/metabolism , Amino Acid Sequence , Electrophoresis, Gel, Two-Dimensional , Molecular Sequence Data , Molecular Weight , Polymerase Chain ReactionABSTRACT
BACKGROUND: Although previous studies reported that the prevalence of Fabry's disease was 0.16 - 1.2% in hemodialysis (HD) patients based on measurement of a-galactosidase A (alpha-Gal A) activity, few reports detected female patients by the screening for alpha-Gal A. Here we determined the prevalence of Fabry's disease not only in male but also in female HD patients by measuring alpha-Gal A. METHODS: Plasma alpha-Gal A was measured in 696 consecutive males (n = 401) and females (n = 295) on HD. Patients with low plasma alpha-Gal A were examined for leukocyte alpha-Gal A, and patients with low leukocyte alpha-Gal A underwent alpha-Gal A gene sequence analysis for possible mutations, and family survey. RESULTS: Among 15 patients with low plasma alpha-Gal A activity, 4 male patients with low leukocyte alpha-Gal A and 1 female patient revealing low plasma alpha-Gal A were detected in 696 HD patients (0.7% of total patients). 3 of these 5 patients were already diagnosed to have the classical type of Fabry's disease. The other 2 patients were newly diagnosed as Fabry's disease, and did not have typical manifestations of Fabry's disease other than renal failure and left ventricular hypertrophy. DNA analysis of these 2 newly diagnosed patients revealed that each had an alpha-Gal missense mutation, previously identified (E66Q, M2961). CONCLUSION: Fabry's disease should be considered in the etiology of unexplained end-stage renal disease. Not only affected males but also affected females undergoing HD patients can be readily diagnosed by alpha-Gal A activities and gene analysis. These patients and their family members may benefit from enzyme replacement therapy for Fabry's disease.